GSK plc (GSK) Form 6-K — Nov 18, 2026
The FDA granted accelerated approval to GSK's Nelkarmi (neladalkib) for adults with previously-treated advanced ALK-positive non-small cell lung cancer, ahead of its original 27 November 2026 target action date. Approval was based on the phase I/II ALKOVE-1 trial, which showed an overall response rate of 49% in patients with only one prior ALK TKI (alectinib) and 32% in heavily pretreated patients, with durable responses and meaningful intracranial activity in CNS metastases.
Key figures
- Original fda action date
- 2026-11-27
- Alkove1 enrolled patients
- 700
- Intracranial orr multi tki
- 26%
- Orr alectinib prior cohort
- 49%
- Orr two or more tki cohort
- 32%
- Intracranial orr alectinib prior
- 55%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.